What is the Unichem Laboratories PE ratio today?
Unichem Laboratories' PE ratio is 11.7 at the 29 October 2026 close (₹504.95 a share): a market capitalisation of ₹3,555 crore divided by consolidated net profit of ₹305 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹253 crore) it is 14.1. These four quarters include net exceptional items of ₹205 crore (one-off gains reported separately), so the ratio on recurring profit would differ.
What is the Unichem Laboratories PB ratio (price to book value)?
Unichem Laboratories' price-to-book (PB) ratio is 1.31 at the 29 October 2026 close: a market capitalisation of ₹3,555 crore divided by shareholders' equity (book value) of ₹2,717 crore on 31 March 2026. That is a book value of ₹386.00 per share against a share price of ₹504.95.
What is the Unichem Laboratories ROE and ROCE?
In FY26, Unichem Laboratories' return on equity (ROE) was 9.8% and its return on capital employed (ROCE) was 2.2%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 5.7% and ROCE 5.6%.
What is the Unichem Laboratories market cap?
Unichem Laboratories' market capitalisation was ₹3,555 crore at the 29 October 2026 close: 7.04 crore shares at ₹504.95 each.
Is Unichem Laboratories debt free?
No. Unichem Laboratories had borrowings of ₹469 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.17. Its cash and current investments were ₹295 crore, so its net debt was ₹174 crore.
What is the Unichem Laboratories EPS?
Unichem Laboratories' basic earnings per share (EPS) were ₹35.91 in FY26, against ₹19.53 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹44.01.
What is the Unichem Laboratories debt to equity ratio?
Unichem Laboratories' debt-to-equity ratio was 0.17 on 31 March 2026: borrowings of ₹469 crore against total equity of ₹2,717 crore. A year earlier, on 31 March 2025, it was 0.18.
What is the Unichem Laboratories promoter holding?
Promoters held 70.22% of Unichem Laboratories on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Unichem Laboratories revenue and profit in FY26?
In FY26 (April 2025–March 2026), Unichem Laboratories' consolidated net profit was ₹253 crore, up 83.9% from ₹138 crore in FY25, on revenue from operations of ₹2,202 crore (up 4.3%).
What is the Unichem Laboratories net worth?
Unichem Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹2,717 crore on 31 March 2026, up 10.9% from ₹2,451 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹3,555 crore at the 29 October 2026 close.
What is the Unichem Laboratories book value per share?
Unichem Laboratories' book value per share was ₹386.00 on 31 March 2026: shareholders' equity of ₹2,717 crore divided by the 7.04 crore shares in issue, up 10.9% from ₹348.10 a year earlier. The share price at the 29 October 2026 close was ₹504.95.
What is the Unichem Laboratories free cash flow?
In FY26, Unichem Laboratories generated ₹3.6 crore of cash from operations and spent ₹123 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹119 crore. In FY25 it was −₹144 crore.
What is the Unichem Laboratories shareholding pattern?
On 30 September 2026, Unichem Laboratories' shares were held by promoters 70.22%, foreign portfolio investors (FII/FPI) 2.70%, domestic institutions (DII) 9.40% (including mutual funds at 8.65%) and retail and other non-institutional investors 17.68%. Over the year, FII holding was up 1.70 percentage points from 1.00% and DII holding was down 1.35 percentage points from 10.75%.
How does Unichem Laboratories compare with its peers?
On FY26 consolidated figures, against Gufic Biosciences, RPG Life Sciences and Gujarat Themis Biosyn: Unichem Laboratories' operating margin of 2.7% is the lowest of the four (Gufic Biosciences 12.8%, RPG Life Sciences 17.8%, Gujarat Themis Biosyn 37.8%; peer average 22.8%); its return on equity of 9.8% is the lowest of the four (Gufic Biosciences 10.1%, RPG Life Sciences 20.3%, Gujarat Themis Biosyn 17.4%; peer average 15.9%).
How does the Unichem Laboratories PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Unichem Laboratories' PE ratio is 14.1, the lowest of the four: Gufic Biosciences 65.4, RPG Life Sciences 43.1 and Gujarat Themis Biosyn 87.7, a peer average of 65.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What are the Unichem Laboratories latest quarterly results?
Unichem Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹41.5 crore, against a loss of ₹10.5 crore in Q1 FY26; revenue from operations ₹633 crore, up 20.1% year on year.
When are the Unichem Laboratories next results?
Unichem Laboratories will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.
Unichem Laboratories vs Gufic Biosciences: how do they compare?
In FY26, Unichem Laboratories earned net profit of ₹253 crore on revenue of ₹2,202 crore, against ₹64.2 crore on ₹944 crore for Gufic Biosciences. Unichem Laboratories' operating margin was 2.7% (Gufic Biosciences 12.8%) and its return on equity 9.8% (Gufic Biosciences 10.1%). At the 29 October 2026 close, Unichem Laboratories' market capitalisation was ₹3,555 crore against ₹4,200 crore for Gufic Biosciences, and its PE ratio on FY26 profit 14.1 against 65.4.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
